Helix BioPharma (TSE:HBP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Helix BioPharma has amended its acquisition agreements with Laevoroc Immunology and Laevoroc Chemotherapy to set fixed numbers of common shares issuable, ensuring flexibility for potential financing deals and protecting shareholder value. The adjustments come ahead of a potential financing opportunity that could affect share dilution and valuation. The transactions will require shareholder approval and adherence to stock exchange conditions.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
